Abstract
AIM
To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray.
METHODS
Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias.
RESULTS
ADL was maintained or slightly improved with THC:CBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in 'standing up' (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THC:CBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THC:CBD oromucosal spray had a positive global impression of change during treatment.
CONCLUSION
In this pilot study, THC:CBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted.
TY - JOUR
T1 - Effect of tetrahydrocannabinol:cannabidiol oromucosal spray on activities of daily living in multiple sclerosis patients with resistant spasticity: a retrospective, observational study.
A1 - Mallada Frechín,Javier,
Y1 - 2018/05/31/
PY - 2018/6/1/pubmed
PY - 2019/1/3/medline
PY - 2018/6/1/entrez
KW - THC:CBD oromucosal spray
KW - activities of daily living
KW - multiple sclerosis
KW - spasticity
SP - 151
EP - 159
JF - Neurodegenerative disease management
JO - Neurodegener Dis Manag
VL - 8
IS - 3
N2 - AIM: To examine evolution in activities of daily living (ADL) in patients with multiple sclerosis spasticity during long-term use of tetrahydrocannabinol (THC):cannabidiol (CBD) oromucosal spray. METHODS: Functional impairment was assessed retrospectively (prior to start of treatment) and at the present moment using a 16-item ADL survey; results were compared. A control group without add-on THC:CBD oromucosal spray was included to investigate possible recall bias. RESULTS: ADL was maintained or slightly improved with THC:CBD oromucosal spray across treatment time (mean 31.9 months) including significant improvement in 'standing up' (p < 0.05) and trends in other items. Significant improvements (p < 0.01) with THC:CBD oromucosal spray were observed in several multiple sclerosis spasticity-related symptoms. Overall, 96.9% of patients using THC:CBD oromucosal spray had a positive global impression of change during treatment. CONCLUSION: In this pilot study, THC:CBD oromucosal spray maintained or improved aspects of daily functioning. Further study in a larger trial is warranted.
SN - 1758-2032
UR - https://www.unboundmedicine.com/medline/citation/29851356/Effect_of_tetrahydrocannabinol:cannabidiol_oromucosal_spray_on_activities_of_daily_living_in_multiple_sclerosis_patients_with_resistant_spasticity:_a_retrospective_observational_study_
L2 - http://www.futuremedicine.com/doi/full/10.2217/nmt-2017-0055?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub=pubmed
DB - PRIME
DP - Unbound Medicine
ER -
